Molecular mechanisms of GBM radioresistance and strategies for radiosensitization

GBM放射抵抗的分子机制及放射增敏策略

• 批准号: 8042256
• 负责人: Sandeep Burma
• 金额: $ 32.89万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8042256
• 关键词: Accounting; Adult; Astrocytes; Brain; Cancer Etiology; Case Study; Cessation of life; DNA; DNA Double Strand Break; DNA Repair Enzymes; DNA-PKcs; Dose; Double Strand Break Repair; Epidermal Growth Factor Receptor; Event; Excision; Gene Dosage; Genetic; Genetic Models; Genome; Genomics; Glioblastoma; Goals; Ionizing radiation; Knockout Mice; Lesion; Link; Malignant Neoplasms; Maps; Methylation; Modality; Molecular; Mus; Mutation; Nonhomologous DNA End Joining; Operative Surgical Procedures; PTEN gene; Pathway interactions; Patients; Phosphorylation; Play; Primary Brain Neoplasms; Radiation; Radiation Induced DNA Damage; Radiation induced double strand break; Radiation therapy; Radiosensitization; Receptor Protein-Tyrosine Kinases; Resistance; Role; Seminal; Signal Pathway; Signal Transduction; System; Testing; The Cancer Genome Atlas; Therapeutic; Treatment Protocols; Tumor Suppressor Proteins; United States; Work; aged; aggressive therapy; base; chemotherapy; epidermal growth factor receptor VIII; improved; mortality; mouse model; nerve stem cell; novel; randomized trial; repaired; success; temozolomide; tumor

DESCRIPTION (provided by applicant): Glioblastoma Multiforme (GBM) tumors are the third leading cause of cancer-related death among adults aged 30 - 50 years, even though they account for less than 1.5% of all new cancer cases reported in the United States each year. The very high mortality rate of GBMs (>90% at 2 years) has remained relatively unchanged over the past 40 years despite aggressive therapy that includes surgical resection, radiotherapy and chemotherapy. However, a clear survival advantage of post-resection radiation has been established by randomized trials, showing that the median survival of GBM patients was improved, from approximately 6 months to 10-12 months, following near-maximal brain-tolerated doses of ionizing radiation. The central role that radiation plays in treating GBM is also illustrated by the landmark Stupp study showing that concurrent radiation and Temozolomide can further increase median survival from 12.1 to 14.6 months. Thus, radiation remains the mainstay of GBM therapy, and the success of the Stupp study, though modest, offers hope that radiotherapy of GBMs can be further improved. Any improvement in therapy would require a more mechanistic understanding of the basis of GBM radioresistance. The lack of improvement in GBM treatment is partly due to a paucity of appropriate genetic models that can be used to delineate the effects of genetic changes that occur in GBMs on radioresistance. The recent mapping of the GBM genome by the Cancer Genome Atlas Network revealed that these tumors have radically altered genomes with many mutations, gene copy number gains and losses, and methylation changes. Amongst the myriad genetic alterations that populate the GBM genomic landscape, 5 key genetic alterations dominate: loss of Ink4a, Arf, p53, or PTEN and amplification of EGFR (especially, the constitutively active EGFRvIII). Which of these key genetic aberrations may confer therapeutic resistance remains unclear. Understanding the contribution of these lesions, singly and in combination, to GBM radioresistance along with the underlying mechanism(s) will be of paramount importance in developing more effective therapeutic modalities. Towards this goal, we plan to use conditional knock out mouse models wherein these key genetic lesions can be introduced in astrocytes and neural stem cells (NSCs) both in culture and in the mouse brain using the Cre-ERT2 system. We propose to examine how these genetic changes impact on mechanisms for the repair of radiation-induced DNA double-strand breaks (DSBs). Based upon our preliminary results, we hypothesize that cross talk between the EGFRvIII-PI3K-Akt axis and the DNA repair enzyme, DNA-PKcs, underlies the radioresistance of GBMs and that this connection can be targeted for effective radiotherapy. Specifically, we propose: 1. To confirm that GBM radioresistance is conferred by interactions between key GBM-specific genetic lesions. 2. To validate that phosphorylation of DNA-PKcs by Akt promotes the repair of radiation-induced DNA breaks. 3. To test whether Akt-DNA-PKcs is a vulnerable node that can be targeted to improve radiotherapy of GBMs. PUBLIC HEALTH RELEVANCE: Narrative Glioblastoma multiforme is the most common and aggressive primary brain tumor in adults and is universally fatal despite aggressive treatment regimens including surgical resection, chemotherapy, and radiotherapy. We propose to understand the basis of radioresistance in glioblastomas and postulate that this is due to proficient repair of radiation-induced DNA damage due to activation of specific signaling pathways by GBM-relevant genetic changes. This would help to identify vulnerable nodes that could be targeted for effective radiosensitization of these tumors.

描述（由申请人提供）：多形性胶质母细胞瘤（GBM）肿瘤是30 - 50岁成年人癌症相关死亡的第三大原因，尽管它们占美国每年报告的所有新癌症病例的不到1.5%。尽管包括手术切除、放疗和化疗在内的积极治疗，GBMs的极高死亡率（2年后约为90%）在过去40年中保持相对不变。然而，随机试验已经证实了切除后放疗的明显生存优势，表明在接近最大脑耐受剂量的电离辐射后，GBM患者的中位生存期从大约6个月提高到10-12个月。具有里程碑意义的Stupp研究也证明了放疗在治疗GBM中的核心作用，该研究表明，同时放疗和替莫唑胺可以进一步将中位生存期从12.1个月增加到14.6个月。因此，放疗仍然是GBM治疗的主要手段，Stupp研究的成功虽然不大，但为GBMs放疗的进一步改进提供了希望。治疗的任何改进都需要对GBM放射耐药的基础有更深入的了解。GBM治疗缺乏改善的部分原因是缺乏适当的遗传模型，这些模型可用于描述GBM中发生的遗传变化对辐射耐药性的影响。最近由癌症基因组图谱网络绘制的GBM基因组图谱显示，这些肿瘤已经从根本上改变了基因组，包括许多突变、基因拷贝数的增加和减少以及甲基化变化。在填充GBM基因组图谱的无数遗传改变中，5个关键的遗传改变占主导地位：Ink4a、Arf、p53或PTEN的缺失和EGFR的扩增（特别是组成活性的EGFRvIII）。目前尚不清楚这些关键的基因畸变中哪一个可能会导致治疗耐药性。了解这些病变（单独或联合）对GBM放射耐药的贡献及其潜在机制，对于开发更有效的治疗方式至关重要。为了实现这一目标，我们计划使用条件敲除小鼠模型，其中这些关键的遗传病变可以使用Cre-ERT2系统在培养和小鼠大脑中的星形胶质细胞和神经干细胞（NSCs）中引入。我们建议研究这些遗传变化如何影响辐射诱导的DNA双链断裂（DSBs）修复机制。根据我们的初步结果，我们假设EGFRvIII-PI3K-Akt轴和DNA修复酶DNA- pkcs之间的串扰是GBMs放射耐药的基础，并且这种连接可以作为有效放疗的靶向。具体而言，我们建议：1。确认GBM辐射抗性是由关键GBM特异性遗传病变之间的相互作用赋予的。2. 验证Akt磷酸化DNA- pkcs促进辐射诱导的DNA断裂的修复。3. 检测Akt-DNA-PKcs是否是可靶向改善GBMs放疗的易损节点。